shaojun peng

Dr. shaojun peng

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
SPshaojun peng
shaojun peng
FXFengfeng Xiao
Fengfeng Xiao
MCMeiwan Chen
Meiwan Chen
huile gaohuile gao
huile gao
The past decades have witnessed great progress in cancer immunotherapy, which has profoundly revolutionized oncology, whereas low patient response rates and potential immune‐related adverse events remain major clinical challenges. With the advantages of controlled delivery and modular flexibility, cancer nanomedicine has offered opportunities to strengthen antitumor immune responses and to sensitize tumor to immunotherapy. Furthermore, tumor‐microenvironment (TME)‐responsive nanomedicine has been demonstrated to achieve specific and localized amplification of the immune response in tumor tissue in a safe and effective manner, increasing patient response rates to immunotherapy and reducing the immune‐related side effects simultaneously. Here, the recent progress of TME‐responsive nanomedicine for cancer immunotherapy is summarized, which responds to the signals in the TME, such as weak acidity, reductive environment, high‐level reactive oxygen species, hypoxia, overexpressed enzymes, and high‐level adenosine triphosphate. Moreover, the potential to combine nanomedicine‐based therapy and immunotherapeutic strategies to overcome each step of the cancer‐immunity cycle and to enhance antitumor effects is discussed. Finally, existing challenges and further perspectives in this rising field with the hope for improved development of clinical applications are discussed.

22 March 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
KWKaixi Wang
Kaixi Wang
KHK.N. Hui
K.N. Hui
Oscar K.S. HUIOscar K.S. HUI
Oscar K.S. HUI
SPshaojun peng
shaojun peng
YXYuxi Xu
Yuxi Xu
This review summarizes comprehensively the latest methods of synthesizing MOFs/graphene and their derivatives, and their application in energy storage and conversion with a detailed analysis of the structure–property relationship.

23 December 2021 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
RLRuncong Liu
Runcong Liu
YPYongjun Peng
Yongjun Peng
LLLigong Lu
Ligong Lu
SPshaojun peng
shaojun peng
TCTianfeng Chen
Tianfeng Chen
MZMeixiao Zhan
Meixiao Zhan
Gas therapy (GT) has attracted increasing attention in recent years as a new cancer treatment method with favorable therapeutic efficacy and reduced side effects. Several gas molecules, such as nitric oxide (NO), carbon monoxide (CO), hydrogen (H2), hydrogen sulfide (H2S) and sulfur dioxide (SO2), have been employed to treat cancers by directly killing tumor cells, enhancing drug accumulation in tumors or sensitizing tumor cells to chemotherapy, photodynamic therapy or radiotherapy. Despite the great progress of gas therapy, most gas molecules are prone to nonspecific distribution when administered systemically, resulting in strong toxicity to normal tissues. Therefore, how to deliver and release gas molecules to targeted tissues on demand is the main issue to be considered before clinical applications of gas therapy. As a specific and noninvasive stimulus with deep penetration, near-infrared (NIR) light has been widely used to trigger the cleavage and release of gas from nano-prodrugs via photothermal or photodynamic effects, achieving the on-demand release of gas molecules with high controllability. In this review, we will summarize the recent progress in cancer gas therapy triggered by NIR light. Furthermore, the prospects and challenges in this field are presented, with the hope for ongoing development.

19 February 2024 in Exploration
Verified
Journal Article
Open access
FWFengshuo Wang
Fengshuo Wang
YFYongliang Fan
Yongliang Fan
YLYue Liu
Yue Liu
XLXiangxin Lou
Xiangxin Lou
LSLinawati Sutrisno
Linawati Sutrisno
Jingchao LiJingchao Li
Jingchao Li
Sonodynamic therapy (SDT) has been explored for cancer therapy, especially for deep tumors due to its low tissue penetration restriction. The therapeutic efficacy of SDT is limited due to the complicated tumor microenvironment. This study reports the construction of oxygen‐carrying semiconducting polymer nanoprodrugs (OSPNpro) for deep tumor treatment via combining amplified SDT with pyroptosis. An oxygen carrier perfluorohexane, sonodynamic semiconducting polymer as the sonosensitizer, and reactive oxygen species (ROS)‐responsive prodrug are co‐loaded into a nanoparticle system, leading to the formation of these polymer nanoprodrugs. Such OSPNpro show an effective accumulation in tumor tissues after systemic administration, in which they deliver oxygen to relieve tumor hypoxia microenvironment and thus mediate amplified SDT via producing ROS under ultrasound (US) irradiation, even when the tumors are covered with a 2‐cm chicken breast tissue. In addition, the ROS‐responsive prodrugs are activated by the generated ROS to trigger pyroptosis of tumor cells. Such a sono‐pyroptosis induces a strong antitumor immunity with obviously higher level infiltrations of effector immune cells into tumors. Therefore, OSPNpro‐based combinational therapy can greatly inhibit the growth of 2‐cm chicken breast tissue‐covered deep tumors and suppress tumor metastasis. This study offers a prodrug nanoplatform for treatment of deep tumor via sono‐pyroptosis strategy.

19 February 2023 in Carbohydrate Polymers
Verified
Journal Article
Closed access
LRLiduo Rong
Liduo Rong
YLYao Liu
Yao Liu
YFYu Fan
Yu Fan
JXJing Xiao
Jing Xiao
YSYanhong Su
Yanhong Su
MZMeixiao Zhan
Meixiao Zhan

6 January 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MZMeixiao Zhan
Meixiao Zhan
XYXiangrong Yu
Xiangrong Yu
WZWei Zhao
Wei Zhao
YPYongjun Peng
Yongjun Peng
SPshaojun peng
shaojun peng
LLLigong Lu
Ligong Lu
Regulation of stimulator of interferon genes (STING) pathway using agonists can boost antitumor immunity for cancer treatment, while the rapid plasma clearance, limited membrane permeability, and inefficient cytosolic transport of STING agonists greatly compromise their therapeutic efficacy. In this study, we describe an extracellular matrix (ECM)-degrading nanoagonist (dNAc) with second near-infrared (NIR-II) light controlled activation of intracellular STING pathway for mild photothermal-augmented chemodynamic-immunotherapy of breast cancer. The dNAc consists of a thermal-responsive liposome inside loading with ferrous sulfide (FeS2) nanoparticles as both NIR-II photothermal converters and Fenton catalysts, 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) as the STING agonist, and an ECM-degrading enzyme (bromelain) on the liposome surface. Mild heat generated by dNAc upon NIR-II photoirradiation improves Fenton reaction efficacy to kill tumor cells and cause immunogenic cell death (ICD). Meanwhile, the generated heat triggers a controlled release of cGAMP from thermal-responsive liposomes to active STING pathway. The mild photothermal activation of STING pathway combined with ICD promotes anti-tumor immune responses, which leads to improved infiltration of effector T cells into tumor tissues after bromelain-mediated ECM degradation. As a result, after treatment with dNAc upon NIR-II photoactivation, both primary and distant tumors in a murine mouse model are inhibited and the liver and lung metastasis are effectively suppressed. This work presents a photoactivatable system for STING pathway and combinational immunotherapy with improved therapeutic outcome. Graphical Abstract